{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:45:40Z","timestamp":1766400340825,"version":"3.37.3"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81471216"],"award-info":[{"award-number":["81471216"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671186"],"award-info":[{"award-number":["81671186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0185865","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T13:46:57Z","timestamp":1507211217000},"page":"e0185865","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis"],"prefix":"10.1371","volume":"12","author":[{"given":"Xinyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-281X","authenticated-orcid":true,"given":"Shaokuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cpr.2014.01.002","article-title":"Psychological treatment of generalized anxiety disorder: a meta-analysis","volume":"34","author":"P Cuijpers","year":"2014","journal-title":"Clin Psychol Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jpsychires.2015.02.017","article-title":"Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis","volume":"64","author":"CU Pae","year":"2015","journal-title":"J Psychiatr Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-clinpsy-050212-185544","article-title":"Worry and generalized anxiety disorder: a review and theoretical synthesis of evidence on nature, etiology, mechanisms, and treatment","volume":"9","author":"MG Newman","year":"2013","journal-title":"Annu Rev Clin Psychol"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/YIC.0b013e32831d7980","article-title":"Efficacy of pregabalin and venlafaxine XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial","volume":"24","author":"S Kasper","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"ref5","first-page":"1661","article-title":"Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients","volume":"9","author":"C Zou","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"e010919","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis","volume":"6","author":"TA Furukawa","year":"2016","journal-title":"BMJ Open"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.jcp.0000084025.22282.84","article-title":"Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder:a pooled analysis of short- and long-term studies","volume":"23","author":"MH Pollack","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0269881108091588","article-title":"A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder","volume":"22","author":"C Allgulander","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4088\/JCP.v67n0511","article-title":"Efficacy and safety of pregabalin in th treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine","volume":"67","author":"SA Montgomery","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0924-9338(03)00046-4","article-title":"A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalized anxiety disorder","volume":"18","author":"D Hackett","year":"2003","journal-title":"Eur Psychiatry"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1532-5415.2002.50003.x","article-title":"Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials","volume":"50","author":"IR Katz","year":"2002","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/da.10141","article-title":"Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder","volume":"19","author":"P Meoni","year":"2004","journal-title":"Dpress anxiety"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"D Moher","year":"2009","journal-title":"BMJ"},{"issue":"Suppl 20","key":"ref14","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview(M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"DV Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"M Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"issue":"Suppl 22","key":"ref16","first-page":"29","article-title":"Clinical guidelines for establishing remission in patients with depression and anxiety","volume":"60","author":"JC Ballenger","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"JP Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.2147\/NDT.S125367","article-title":"Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Y Okuyama","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"e0175708","DOI":"10.1371\/journal.pone.0175708","article-title":"Patients with subclinical hypothyroidism before 20 weeks of pregnancy have a higher risk of miscarriage: a systematic review and meta-analysis","volume":"12","author":"Y Zhang","year":"2017","journal-title":"PLoS ONE"},{"issue":"7109","key":"ref20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"e0176068","DOI":"10.1371\/journal.pone.0176068","article-title":"The relationship between diabetes and colorectal cancer prognosis: a meta-analysis based on the cohort studies","volume":"12","author":"B Zhu","year":"2017","journal-title":"PLoS ONE"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"e0166833","DOI":"10.1371\/journal.pone.0166833","article-title":"Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis","volume":"11","author":"FP Wang","year":"2016","journal-title":"PLoS ONE"},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v60n0805","article-title":"Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder","volume":"60","author":"JR Davidson","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","article-title":"Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder","volume":"157","author":"K Rickels","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00004850-200411000-00003","article-title":"Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study","volume":"19","author":"I Nimatoudis","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/YIC.0b013e32807fb1b2","article-title":"Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial","volume":"22","author":"J Hartford","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/da.20355","article-title":"Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder","volume":"25","author":"A Bose","year":"2008","journal-title":"Depress Anxiety"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S0033291708003401","article-title":"Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial","volume":"39","author":"H Nicolini","year":"2009","journal-title":"Psychol Med"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1017\/S1092852900021544","article-title":"Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER","volume":"12","author":"SM Stahl","year":"2007","journal-title":"CNS Spectr"},{"issue":"9665","key":"ref30","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"A Cipriani","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40273-013-0031-z","article-title":"The cost effectiveness of pharmacological treatments for generalized anxiety disorder","volume":"31","author":"I Mavranezouli","year":"2013","journal-title":"Pharmacoeconomics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0185865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T21:37:45Z","timestamp":1540244265000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0185865"}},"subtitle":[],"editor":[{"given":"Emilio","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0185865","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}